| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IPO7 |
| Uniprot No | O95373 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1038aa |
| 氨基酸序列 | MDPNTIIEALRGTMDPALREAAERQLNEAHKSLNFVSTLLQITMSEQLDLPVRQAGVIYLKNMITQYWPDRETAPGDISPYTIPEEDRHCIRENIVEAIIHSPELIRVQLTTCIHHIIKHDYPSRWTAIVDKIGFYLQSDNSACWLGILLCLYQLVKNYEYKKPEERSPLVAAMQHFLPVLKDRFIQLLSDQSDQSVLIQKQIFKIFYALVQYTLPLELINQQNLTEWIEILKTVVNRDVPNETLQVEEDDRPELPWWKCKKWALHILARLFERYGSPGNVSKEYNEFAEVFLKAFAVGVQQVLLKVLYQYKEKQYMAPRVLQQTLNYINQGVSHALTWKNLKPHIQGIIQDVIFPLMCYTDADEELWQEDPYEYIRMKFDVFEDFISPTTAAQTLLFTACSKRKEVLQKTMGFCYQILTEPNADPRKKDGALHMIGSLAEILLKKKIYKDQMEYMLQNHVFPLFSSELGYMRARACWVLHYFCEVKFKSDQNLQTALELTRRCLIDDREMPVKVEAAIALQVLISNQEKAKEYITPFIRPVMQALLHIIRETENDDLTNVIQKMICEYSEEVTPIAVEMTQHLAMTFNQVIQTGPDEEGSDDKAVTAMGILNTIDTLLSVVEDHKEITQQLEGICLQVIGTVLQQHVLEFYEEIFSLAHSLTCQQVSPQMWQLLPLVFEVFQQDGFDYFTDMMPLLHNYVTVDTDTLLSDTKYLEMIYSMCKKVLTGVAGEDAECHAAKLLEVIILQCKGRGIDQCIPLFVEAALERLTREVKTSELRTMCLQVAIAALYYNPHLLLNTLENLRFPNNVEPVTNHFITQWLNDVDCFLGLHDRKMCVLGLCALIDMEQIPQVLNQVSGQILPAFILLFNGLKRAYACHAEHENDSDDDDEAEDDDETEELGSDEDDIDEDGQEYLEILAKQAGEDGDDEDWEEDDAEETALEGYSTIIDDEDNPVDEYQIFKAIFQTIQNRNPVWYQALTHGLNEEQRKQLQDIATLADQRRAAHESKMIEKHGGYKFSAPVVPSSFNFGGPAPGMN |
| 预测分子量 | 119,5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IPO7重组蛋白的3篇虚拟参考文献(基于领域常见研究方向虚构，仅供参考)：
---
1. **文献名称**: *Expression and Purification of Recombinant IPO7 in Escherichia coli for Nuclear Transport Studies*
**作者**: Zhang L, et al.
**摘要**: 本研究报道了在大肠杆菌系统中高效表达并纯化人源IPO7重组蛋白的方法，验证了其与典型核定位信号(NLS)肽段的体外结合能力，为研究核质运输机制提供了工具。
2. **文献名称**: *Structural Insights into IPO7-Mediated Viral Protein Import*
**作者**: Kim S, Patel RR.
**摘要**: 通过冷冻电镜解析了IPO7重组蛋白与病毒蛋白复合物的结构，揭示了IPO7如何识别病毒蛋白的特定NLS结构域，为抗病毒药物设计提供结构基础。
3. **文献名称**: *Functional Analysis of IPO7 in Cancer Cell Proliferation via Recombinant Protein Complementation*
**作者**: García-Molina A, et al.
**摘要**: 利用重组IPO7蛋白恢复缺失细胞系的核转运功能，证明IPO7通过调控p53等肿瘤抑制因子的核定位影响癌细胞增殖，提示其作为癌症治疗靶点的潜力。
---
注：上述文献为示例性虚构内容，实际研究中请通过PubMed、Google Scholar等平台检索真实文献。
IPO7 (Importin-7), a member of the importin β family of nuclear transport receptors, plays a critical role in mediating nucleocytoplasmic transport by shuttling macromolecules across the nuclear pore complex. It binds to cargo proteins containing nuclear localization signals (NLS) or other specific recognition motifs, facilitating their entry into the nucleus. IPO7 is involved in diverse cellular processes, including cell cycle regulation, gene expression, and viral replication, as it interacts with substrates such as ribosomal proteins, transcription factors, and viral integrases (e.g., HIV-1 integrase). Dysregulation of IPO7 has been linked to diseases like cancer, where its overexpression may influence tumor progression by modulating nuclear transport of oncogenic factors.
Recombinant IPO7 protein is engineered using expression systems like *E. coli* or mammalian cells, followed by purification via affinity chromatography. Its production enables detailed *in vitro* studies on nuclear transport mechanisms, cargo specificity, and interactions with therapeutic targets. Researchers utilize recombinant IPO7 to investigate viral pathogenesis, particularly HIV-1 replication, as IPO7 assists in nuclear import of the viral pre-integration complex. Additionally, it serves as a tool for screening small-molecule inhibitors that could block pathogenic nuclear transport processes. The protein’s structural and functional characterization also contributes to understanding cellular homeostasis and developing strategies to correct transport-related dysfunctions in diseases. Recombinant IPO7’s high purity and activity make it valuable for both basic research and drug discovery applications.
×
